01—Abstract
Summary
Summary of the 8-K filed May 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. (GILD) has filed an 8-K detailing the outcomes of its 2026 annual meeting of stockholders held on April 30, 2026.
The meeting saw a strong turnout, with approximately 91%a of outstanding shares represented, establishing a quorum. Key outcomes include the re-election of all nine director nominees, with overwhelming support across the board. Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company's Named Executive Officers.
Furthermore, investors approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan, indicating continued support for executive and employee long-term incentives. However, several significant stockholder proposals did not receive majority approval, including those requesting an independent Board Chair, a report on the impact of extended patent exclusivities on patient access, and a report on the risks of ESG and DEI executive compensation metrics. These results suggest that while the board's composition and executive compensation received stockholder backing, there was a lack of consensus on certain governance and policy-related initiatives proposed by shareholders.
02—Key points
Key Highlights
- All nine director nominees were re-elected with substantial 'For' votes, indicating strong shareholder confidence in the current board.
- Ernst & Young LLP was ratified as Gilead's independent registered public accounting firm for fiscal year 2026.
- Shareholders approved, on an advisory basis, the compensation of Gilead's Named Executive Officers.
- The amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan was approved by stockholders.
- A stockholder proposal requesting an independent Board Chair policy was not approved.
- Stockholder proposals requesting reports on patent exclusivities' impact on patient access and ESG/DEI executive compensation risks also failed to gain majority approval.
03—Questions
Frequently Asked Questions
What were the key outcomes of Gilead's 2026 annual stockholder meeting?
The key outcomes include the re-election of all nine directors, ratification of Ernst & Young LLP as the independent auditor, advisory approval of executive compensation, and approval of the amended 2022 Equity Incentive Plan. Several stockholder proposals concerning board independence, patent exclusivity impacts, and ESG/DEI compensation metrics did not pass.
Did shareholders approve the company's executive compensation?
Yes, shareholders approved the compensation of Gilead's Named Executive Officers on an advisory basis, with approximately 954 million 'For' votes versus approximately 77 million 'Against' votes.
Were there any significant stockholder proposals that failed to pass?
Yes, three stockholder proposals did not receive majority approval: one requesting an independent Board Chair policy, another asking for a report on the impact of extended patent exclusivities on patient access, and a third seeking a report on the risks associated with ESG and DEI executive compensation metrics.
What was the level of shareholder participation at the meeting?
Shareholder participation was robust. Out of 1,241,222,013 shares entitled to vote, 1,130,179,690 shares, or approximately 91%, were represented in person or by proxy, establishing a quorum.
04—Continue